In­tel­liphar­ma­ceu­tics shares crushed as FDA ex­perts snub pain drug; Mon­cef Slaoui joins Mod­er­na board

→ Af­ter get­ting chas­tised by reg­u­la­tors in an in­ter­nal FDA re­view of Toron­to-based In­tel­liphar­ma­ceu­tics‘ $IP­CI new pain drug Rex­ista, a pan­el of out­side ex­perts joined in, vot­ing to rec­om­mend a re­jec­tion of the ther­a­py. Billed as a new ver­sion of oxy with new fea­tures which the biotech claimed would de­ter abuse, the pan­elists vot­ed 22 to 1 against an OK. And all of them agreed that the com­pa­ny nev­er of­fered the da­ta that would be need­ed to gain an abuse-de­ter­rent note on the la­bel, if it were to be ap­proved. The com­pa­ny’s shares cratered, drop­ping 45%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER